Duramed’s ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Tablets Receives Two New FDA Approvals

Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), today announced that the Company has received two U.S. Food and Drug Administration (FDA) approvals related to its ENJUVIA(TM) (synthetic conjugated estrogens, B) product. The FDA has approved the Company’s supplemental New Drug Application (sNDA) for 0.9 mg tablet strength, which will be added to the Company’s existing ENJUVIA product line that includes the 0.3 mg, 0.45 mg, 0.625 mg, and 1. [click link for full article]

Read More: continued here

Filed under: Endocrinology on May 7th, 2007